AVI BioPharma Announces NeuGene Antisense Collaboration With USAMRIID on Biodefense Agents
"Our previous work with USAMRIID and their experience with our NeuGene compounds led to establishing this formal CRADA relationship to pursue testing and development of our antisense technology against a broad range of potential biodefense infections," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "Our programs will benefit greatly from USAMRIID researchers' experience with these bioterror agents, and working with USAMRIID will strengthen our pursuit of effective therapeutics in this area."
AVI believes its NeuGene antisense "rapid response therapeutics" have a significant role to play in the future of antiviral therapeutics. NeuGeneS are synthetic compounds that mirror a critical portion of a disease-causing organism's genetic code and bind to specific portions of the target genetic sequence. Like a key in a lock, NeuGene antisense compounds are designed to match up precisely with a specific gene or viral sequence, blocking the function of the target gene or virus.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.